Differences in Health-Related Outcomes Across Antipsychotic Treatments in Patients With Schizophrenia and Bipolar Disorder

December 15, 2017
Download Poster (594.27 KB)

 

This poster was presented at the 30th annual  Psych Congress, held Sept. 16-19, 2017, in New Orleans, Louisiana.

Objectives: This study assessed health-related outcomes associated with the use of lurasidone and other antipsychotic agents among patients with schizophrenia or bipolar disorder in the U.S.

Methods: Patients (≥18 years) with schizophrenia or bipolar disorder were retrospectively identified in the More2 Database (2012-2014). Treatment episodes began with first antipsychotic fill (index date) and were censored upon either (i) 45 days without antipsychotic, or (ii) benefit coverage termination. Two consecutive fills were required. Antipsychotics of interest included aripiprazole, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone, and first-generation antipsychotics. Annualized prescription fills, office, outpatient hospital, ER, and inpatient hospitalizations for lurasidone vs. comparators were assessed using multivariate regression models.

Results: The study included 38,544 patients (40% schizophrenia, 60% bipolar, mean age=45.4 years, 58.6% female). Treatment duration was 211±174 days. Lurasidone-treated schizophrenia patients filled 8-17% more prescriptions than all comparators except ziprasidone, but had 15-23% fewer hospitalizations compared to all other antipsychotics (Ps<0.05). Office, outpatient hospital, and ER visits among patients with schizophrenia were not significantly different.

Lurasidone-treated bipolar patients filled 7-10% more prescriptions than all comparators except ziprasidone and first-generation antipsychotics, had 5-8% more office visits compared to all comparators except olanzapine and ziprasidone, experienced 7-28% fewer outpatient hospital visits than olanzapine, quetiapine, risperidone, and first-generation antipsychotics, and had 14-18% fewer hospitalizations than aripiprazole, olanzapine, quetiapine, and risperidone, (Ps<0.05). No significant difference was observed in ER visits among patients with bipolar disorder.

Conclusion: Among patients with schizophrenia or bipolar disorder, lurasidone was associated with fewer hospitalizations and greater prescription utilization than other antipsychotic agents.

Authors: 
Daisy Ng-Mak, PhD; Andrew Messali, PharmD, PhD; Krithika Rajagopalan, PhD; Joseph Tkacz, MS; Brenna L. Brady, PhD; Charles Ruetsch, PhD; Antony Loebel, MD
Sponsoring Organization: 
Sunovion Pharmaceuticals Inc.
Year: 
2017
Tracks: 
Child & Adolescent Psychiatry
Schizophrenia